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Regulatory Aspects of Allergen-Specific Immunotherapy:
Europe Sets the Scene for a Global Approach
Sergio Bonini, MD
After 100 years from its introduction in the treatment ofallergic patients,1–3 regulatory aspects of allergen-speciﬁc
immunotherapy (ASI) are still incompletely deﬁned and very
heterogeneous among different countries.
To better understand the scenario of regulatory docu-
ments applying to ASI in Europe and their different compelling
value, it might be useful, for pure didactic purposes of this
article and in agreement with the thoughtful paper of Kaul
et al,4 to classify them according to a hierarchic scale (from A
to D), as in the Shekelle ranking of the level of evidence of
scientiﬁc statements.5
Type A documents are represented by European Com-
munity (EC) Regulations, which are valid and compelling for
all Member States. The same value can be assigned to the
European Pharmacopeia, which includes a speciﬁc Mono-
graph on Allergen Products.
Among Type B documents, we can include EC Direc-
tives. These are not compelling for Member States, which
however are obliged to adapt to the Directives by producing
national laws within a given period.
Type C documents may be represented by the European
Medicine Agency (EMA) Guidelines. These have only value
of orientation, mainly for clinical trials (which should however
justify, in case of discrepancies, why guidelines were not
followed). A special type of guideline is represented by the
International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceutical for Human
Use (ICH), a consensus document agreed on by the European,
American, and Japanese Regulatory Agencies.
Position Papers or Practice Parameters of Expert Panels
or of Scientiﬁc Societies6–12 can be considered as Type D
documents because they only represent individual opinions,
even if evidence based, certainly useful for clinical practice
but of no regulatory value.
As in the Shekelle classiﬁcation, the different types of
evidence imply a corresponding level of strength of recom-
mendations, documents on immunotherapy have a different
regulatory impact, mandatory for European Regulations and
National Laws following EC Directives, of orientation only
for Types C and D documents.
Table 1 reports some examples of regulatory documents
for IAS distinguished according to the categories described
above.
THE PRESENT
Allergen products have been marketed for many years
in Europe as named patient products (NPP), following
a marketing authorization, which had only to answer to
Good Manufacturing Practice requirements. Accordingly, the
pharmacovigilance system for ASI is poorly structured, being
only based on the voluntary reporting of side effects by
doctors and patients. This generated from one side a diffuse
skepticism among nonallergy specialists on the efﬁcacy of
the treatmentddespite the results of several meta-analysis of
Randomized Clinical Trials (RCTs) after the original one
published in 195413das well as a perhaps excessive and
unjustiﬁed alarm on its safety, particularly in England.
In Europe, a crucial turning point in the regulatory
aspects of ASI has been produced by the Directive 2001/20/
EC and its amending Directive 2003/63/EC. These Directives
state 2 fundamental issues for allergen products used both for
in vivo diagnostics and for ASI of allergic diseases:
1. Allergens are medicines because they are capable to
identify or to induce an acquired change in the immune
response to a sensitizing agent.
2. As medicines produced with an industrial process, aller-
gens therefore require, in Europe, a marketing authori-
zation according to the procedures established for all
drugs (ie, centralized, mutual recognition, decentralized,
or national14–17) and following a clinical development
through all phases of RCTs.
In fact, the Directive 2001/83 also establishes that in
special circumstances, NPP may be prescribed for individual
patients under the direct doctor responsibility. This exception
is responsible for the different behaviors adopted in different
European countries, depending on the national legislation
and on the prevalent use of NPP versus registered allergen
products.4,18
The EMA and the new Executive Director (see box) is
now considering to come, through a discussion open to all
stakeholders including the World Allergy Organization (WAO)
and the European Academy of Allergy and Clinical Immunol-
ogy EAACI, to a more uniform approach in Europe on ASI,
which might also represent the basis for a more global consensus
with other regulatory agencies.
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THE FUTURE
The high prevalence of allergic diseases and their
chronic coursedthat are responsible for high costs for both
individuals and the Societydshould give to ASI a high pri-
ority in the agenda of all national and international regulatory
bodies. Furthermore, because allergic diseases are a global
problem, national approaches should be harmonized, to
avoid, for instance, the discrepancies at present observed
between Europe and the United States19–21 and to allow a uni-
form standard of care in any part of the world.
Of course, different economic resources and health
priorities among countries may certainly inﬂuence access to
AIS and reimbursement policies. However, the same efﬁcacy
and safety requirements should be assured to any citizen
independently from the place of residence, also taking into
account the actual high degree of mobility.
There is no doubt that ASI products should be
supported by adequate preclinical and clinical dossiers for
both adults and children, as for all other drugs. This will
imply a hard commitment for both allergen manufacturers
and research scientists in providing high-quality allergens,
TABLE 1. Types of Regulatory Documents for Allergen-Specific Immunotherapy
Type Examples
A
 Regulation No. 726/2004/EC laying down Community Procedures for the authorization
and supervision of medicinal products for human and veterinary use and establishing
a EMA. OJ 2004;136:1–33.
 Regulation No. 1901/2001/EC on medicinal products for pediatric use and amending
Regulation EEC No. 1768/92, Directive 2001/83/EC, and Regulation No.
726/2004/EC OJ 2006;378:1–19.
 European Pharmacopeia, Monograph on allergen products. 01/2010:1063
B
 Directive 2001/83/EC of the European Parliament and of the Council on the community
code relating to medicinal products for human use. OJ 2004;1,341:67–112.
 Directive 2001/20/EC of the European Parliament and of the Council on the approximation
of the laws, regulations, and administrative provisions of the Member States relating to
the implementation of good clinical practice in the conduct of clinical trials on medicinal
products for human use. OJ 2001;1,121:24–44.
 Commission Directive 2003/63/EC amending Directive 2001/83/EC. OJ 2003/1.159:46–94.
 Commission Directive 2003/94/EC laying down the principles and guidelines of good
manufacturing practice in respect of medicinal products for human use and investigational
medicinal products for human use. OJ 2003;262:22–26.
C
 EMA Guideline on Allergen Products: Production and Quality Issues.
2008. EMEA. CHMP/BWP/30483!/2007
 Referring to both allergen extracts (and their classiﬁcation in homologous groups) and
allergens produced trough recombinant technology
 EMA Note for Guidance on Preclinical Pharmacological and Toxicological Testing of
Vaccines. 1998/CPMP/SWP/465/95
 ICH Topic M3 (R2). Note for guidance on non-clinical safety studies for the conduct
of Human clinical trials and marketing authorization for pharmaceuticals. 2009.CPMP/ICH/286/95
 ICH Topic E6 (R1). Note for guidance on GPC. 2002.CPMP/ICH/135/95
 ICH Topic E9. Note for guidance on statistical principles for clinical trials.
1998.CPMP/ICH/135/95
 Points to consider on application with: 1.Meta-analyses; 2.One pivotal study.
2001.CPMP/EWP/2330/99
 EMA Guideline on the Clinical Development of Products for SIT for the treatment
of allergic Diseases. 2008.CHMP/EWP/18504/2006
 EMA/PDCO Standard Paediatric Investigation Plan for Allergen Products for Speciﬁc
Immunotherapy. EMA/PDCO/737605/2009. Revision 2, 3-3-2010.
D
 Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper6
 Recommendations for standardization of clinical trials with allergen-speciﬁc Immunotherapy
for respiratory allergy. A statement of the World Allergy Organization Task Force7
 Sublingual immunotherapy. WAO Position Paper8
 EAACI Immunotherapy Position Paper9
 Allergen immunotherapy. A practice parameter. Third Update10
 Allergen immunotherapy in children. An EAACI position statement11
 The CONSORT statement checklist in allergen speciﬁc immunotherapy. A GA2LEN paper12a,b
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deﬁning adequate study designs, selecting distinct pheno-
types of patients on the basis of reliable clinical and
biological markers,22,23 identifying clinically relevant
objective and patient-related outcome measures, such as
quality-of-life outcome measures. These should be selected
depending on which of the 4 potential claims of ASI that,
according to EMA Guidelines, should receive support in
future clinical trials:
• Treatment of allergic symptoms: efﬁcacy in short-term
clinical trials in the ﬁrst pollen season or, in perennial
allergies, after some months of treatment;
• Sustained clinical effect: maintenance of signiﬁcant
and clinically relevant efﬁcacy during 2 to 3 treatment
years;
• Long-term efﬁcacy and disease modifying effect: sus-
tained signiﬁcant and clinically relevant efﬁcacy in post-
treatment years;
• Curing allergy: sustained absence of allergic symptoms
in posttreatment years.
Clinical trials in children should follow the EMA
Standard Pediatric Investigation Plan. However, this has
possibly to be reconsidered, to allow the feasibility and ethics
required for studies in this particular population sample.
Finally, outcome measures of future clinical trials should
also include pharmacoeconomic end points that may allow
a beneﬁt/risk assessment, particularly for the most severe forms
of allergic diseases still waiting for adequate treatment.
It is important to note that regulatory issues of ASI will
certainly reﬂect on the rights of patients to have access to an
optimal heath care and on a core competence of allergists. In
fact, it can be expected from one side that a reduced number
of allergen products will enter and pass the long and
expensive process of registration and from the other side that
products obtaining a marketing authorization will be more
easily available for prescription to other specialists. Accord-
ingly, a specialty based on skin-prick testing aimed at ASI
prescription, in the lack of speciﬁc irreplaceable competences,
will have no more reasons to survive the unavoidable cuts of
the various national health systems. On the other hand, rare
and severe allergies may still need specialized diagnostic
approaches and availability of orphan products. The new
Allergy specialist should therefore adapt to the changing
health needs, hear the last call not to forget to be also
a Clinical Immunology specialist, and enlarge his/her com-
petence to the growing ﬁeld of Biologicals.
In conclusion, the second Century of ASI may open
a new era for all stakeholders in the area of Allergy and
Clinical Immunology,24 which hopefully may reﬂect on a bet-
ter management of the increasing number of patients with
allergic and immunologic diseases.
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